WallStSmart

Agnico Eagle Mines Limited (AEM)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agnico Eagle Mines Limited generates 11% more annual revenue ($13.54B vs $12.22B). AEM leads profitability with a 39.5% profit margin vs 35.5%. VRTX appears more attractively valued with a PEG of 2.10. AEM earns a higher WallStSmart Score of 75/100 (B+).

AEM

Strong Buy

75

out of 100

Grade: B+

Growth: 10.0Profit: 9.5Value: 4.7Quality: 8.5
Piotroski: 6/9Altman Z: 2.83

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMOvervalued (-12.6%)

Margin of Safety

-12.6%

Fair Value

$192.97

Current Price

$193.21

$0.24 premium

UndervaluedFair: $192.97Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEM6 strengths · Avg: 9.8/10
Profit MarginProfitability
39.5%10/10

Keeps 40 of every $100 in revenue as profit

Operating MarginProfitability
62.8%10/10

Strong operational efficiency at 62.8%

Revenue GrowthGrowth
66.1%10/10

Revenue surging 66.1% year-over-year

EPS GrowthGrowth
108.6%10/10

Earnings expanding 108.6% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$93.89B9/10

Large-cap with strong market position

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

AEM1 concerns · Avg: 2.0/10
PEG RatioValuation
28.152/10

Expensive relative to growth rate

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AEM

The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 39.5% and operating margin at 62.8%. Revenue growth of 66.1% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : AEM

The primary concerns for AEM are PEG Ratio.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

AEM profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

AEM carries more volatility with a beta of 0.57 — expect wider price swings.

AEM is growing revenue faster at 66.1% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

AEM scores higher overall (75/100 vs 66/100), backed by strong 39.5% margins and 66.1% revenue growth. VRTX offers better value entry with a 57.2% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agnico Eagle Mines Limited

BASIC MATERIALS · GOLD · USA

Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?